These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30899593)

  • 1. Repin1 deficiency in liver tissue alleviates NAFLD progression in mice.
    Abshagen K; Mense L; Fischer F; Liebig M; Schaeper U; Navarro G; Glass Ä; Frank M; Klöting N; Vollmar B
    J Adv Res; 2019 Mar; 16():99-111. PubMed ID: 30899593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver-specific Repin1 deficiency impairs transient hepatic steatosis in liver regeneration.
    Abshagen K; Degenhardt B; Liebig M; Wendt A; Genz B; Schaeper U; Stumvoll M; Hofmann U; Frank M; Vollmar B; Klöting N
    Sci Rep; 2018 Nov; 8(1):16858. PubMed ID: 30442920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver-restricted Repin1 deficiency improves whole-body insulin sensitivity, alters lipid metabolism, and causes secondary changes in adipose tissue in mice.
    Kern M; Kosacka J; Hesselbarth N; Brückner J; Heiker JT; Flehmig G; Klöting I; Kovacs P; Matz-Soja M; Gebhardt R; Krohn K; Sales S; Abshagen K; Shevchenko A; Stumvoll M; Blüher M; Klöting N
    Diabetes; 2014 Oct; 63(10):3295-309. PubMed ID: 24760138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repin1 deficiency improves insulin sensitivity and glucose metabolism in db/db mice by reducing adipose tissue mass and inflammation.
    Kunath A; Hesselbarth N; Gericke M; Kern M; Dommel S; Kovacs P; Stumvoll M; Blüher M; Klöting N
    Biochem Biophys Res Commun; 2016 Sep; 478(1):398-402. PubMed ID: 27402271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Human REPIN1 Gene Variant: Genetic Risk Factor for the Development of Nonalcoholic Fatty Liver Disease.
    Abshagen K; Berger C; Dietrich A; Schütz T; Wittekind C; Stumvoll M; Blüher M; Klöting N
    Clin Transl Gastroenterol; 2020 Jan; 11(1):e00114. PubMed ID: 31922994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human germline hedgehog pathway mutations predispose to fatty liver.
    Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
    J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
    Zhou ST; Cui W; Kong L; Yang X
    Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
    Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
    Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
    Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
    Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAR2 deficiency ameliorates non-alcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.
    Kung ML; Yang TH; Lin CC; Ho JY; Hung TC; Chang CH; Huang KW; Chen CC; Chen YW
    J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):949-962. PubMed ID: 38533529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockout of STE20-type kinase TAOK3 does not attenuate diet-induced NAFLD development in mice.
    Xia Y; Andersson E; Caputo M; Cansby E; Sedda F; Font-Gironès F; Ruud J; Kurhe Y; Hallberg B; Marschall HU; Asterholm IW; Romeo S; Blüher M; Mahlapuu M
    Mol Med; 2023 Oct; 29(1):138. PubMed ID: 37864157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
    Fu D; Cui H; Zhang Y
    Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis.
    Herrero-Cervera A; Vinué Á; Burks DJ; González-Navarro H
    Diabetologia; 2019 Nov; 62(11):2143-2157. PubMed ID: 31388695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions.
    Liu J; Jiang S; Zhao Y; Sun Q; Zhang J; Shen D; Wu J; Shen N; Fu X; Sun X; Yu D; Chen J; He J; Shi T; Ding Y; Fang L; Xue B; Li C
    J Pathol; 2018 Nov; 246(3):277-288. PubMed ID: 29971772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of altered hepatic gene expression in American lifestyle-induced obesity syndrome diet-fed mice with metabolic changes during NAFLD development and progression.
    Iannone V; Lok J; Babu AF; Gómez-Gallego C; Willman RM; Koistinen VM; Klåvus A; Kettunen MI; Kårlund A; Schwab U; Hanhineva K; Kolehmainen M; El-Nezami H
    J Nutr Biochem; 2023 May; 115():109307. PubMed ID: 36868506
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Huang Y; Cao J; Zhu M; Wang Z; Jin Z; Xiong Z
    Microbiol Spectr; 2024 Apr; 12(4):e0339323. PubMed ID: 38411057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repin1 maybe involved in the regulation of cell size and glucose transport in adipocytes.
    Ruschke K; Illes M; Kern M; Klöting I; Fasshauer M; Schön MR; Kosacka J; Fitzl G; Kovacs P; Stumvoll M; Blüher M; Klöting N
    Biochem Biophys Res Commun; 2010 Sep; 400(2):246-51. PubMed ID: 20727851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of bioactive components and synergistic action mechanism of ShuGan-QieZhi Capsule for treating non-alcoholic fatty liver disease.
    Zhu T; Huang X; Zhu H; Chen J; Yao H; Zhang Y; Hua H; Zhang J; Qi J
    Phytomedicine; 2024 Jan; 123():155173. PubMed ID: 37976695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.